|Day's Range||0.0051 - 0.0066|
|52 Week Range||0.0051 - 0.2500|
|PE Ratio (TTM)||-0.13|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Yahoo Finance Get free summary analysis Interleukin Genetics, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Interleukin Genetics, Inc. – Psychemedics Corporation, Genomic Health, Inc., RadNet, Inc., Quest Diagnostics Incorporated, Myriad Genetics, Inc. and Trovagene, Inc. (PMD-US, GHDX-US, RDNT-US, DGX-US, MYGN-US and TROV-US) that ... Read more (Read more...)
By Brian Marckx, CFA OTC:ILIU Q4 2015 : PerioPredict Adoption Still Slow, But Making Progress. Top-Notch Clinical Advisory Board Brought On Interleukin Genetics (OTC:ILIU) reported financial results for ...
By Brian Marckx, CFA OTC:ILIU Metagenics Will Utilize PerioPredict in Benefit Plans : Interleukin Genetics (OTC:ILIU) announced last week that Metagenics will use PerioPredict in their employee benefit ...